Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Sunday. The brokerage issued a sell rating on the stock.

Separately, Roth Mkm reaffirmed a buy rating and set a $20.00 price objective on shares of Bio-Path in a research note on Monday, July 8th.

Bio-Path Stock Performance

Shares of NASDAQ BPTH opened at $0.88 on Friday. The stock’s 50-day simple moving average is $1.21 and its two-hundred day simple moving average is $2.20. Bio-Path has a twelve month low of $0.86 and a twelve month high of $21.60.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same quarter in the previous year, the business earned ($10.60) earnings per share. On average, equities analysts anticipate that Bio-Path will post -6.2 EPS for the current fiscal year.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to its most recent filing with the SEC. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the SEC. Institutional investors own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.